CertaraCERT +2.50%59 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus rates CERT with a GF Score™ of 59/100 and a GF Value™ of $13.40 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 621 Healthcare Providers & Services companies, Certara ranks worse than 161030.43% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Certara's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Certara's 3-Year ROIIC % or its related term are showing as below:
CERT's 3-Year ROIIC % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.59 * Ranked among companies with meaningful 3-Year ROIIC % only.
Certara (NAS:CERT) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Certara 3-Year ROIIC % Related Terms
Certara 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Certara's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERT vs TALK, GDRX, OMDA: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Certara's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Certara's 3-Year ROIIC % falls into.
Certara's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 0 (Dec. 2025) - 25.5419934 (Dec. 2022) )
/
( 1384.331 (Dec. 2025) - 1324.407 (Dec. 2022) )
=
/
59.924
=
0.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Certara (CERT) has a 3-Year ROIIC % of 0.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Certara and its competitors. According to the industry distribution chart, Certara ranks #999999 out of 621 companies in the Healthcare Providers & Services industry.
Is Certara's 3-Year ROIIC % too high?
Certara's current 3-Year ROIIC % is 0.00. Based on the distribution chart, Certara ranks #999999 out of 621 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Certara has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Certara's 3-Year ROIIC % compare to TALK and GDRX?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #999999 out of 621 companies for 3-Year ROIIC %. This places Certara in the lower half of its industry. The industry median 3-Year ROIIC % is 2.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 2.59, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Certara and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Possible Value Trap. The stock's GF Value™ is $13.40, compared to a current price of $5.54 — trading 58.7% below its estimated fair value. The current 3-Year ROIIC % is 0.00. Certara's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Certara (CERT), the current 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $5.54 is trading 58.7% below its estimated GF Value™ of $13.40.
GuruFocus considers Certara to be Possible Value Trap.
Key valuation signals for CERT:
3-Year ROIIC %: 0.00
GF Value™: $13.40 vs. price of $5.54 (58.7% below fair value)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
59GF Score
Get the complete analysis for CERT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
